Body Weight Changes with β-Blocker Use: Results from GEMINI

American Journal of Medicine

Volumn 120, Issue 7, 2007, Pages 610-615

  Messerli, Franz H ^a   Bell, David S H ^b   Fonseca, Vivian ^c   Katholi, Richard E ^d   McGill, Janet B ^e   Phillips, Robert A ^f   Raskin, Philip ^g   Wright Jr , Jackson T ^h   Bangalore, Sripal ^a   Holdbrook, Fred K ⁱ   Lukas, Mary Ann ⁱ   Anderson, Karen M ⁱ   Bakris, George L ^j  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c TULANE UNIVERSITY   (United States)

^d ST JOHN'S HOSPITAL   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Memorial Medical Center   (United States)

^g UNIVERSITY OF TEXAS AT DALLAS   (United States)

^h CASE WESTERN RESERVE UNIVERSITY   (United States)

ⁱ GLAXOSMITHKLINE   (United States)

^j RUSH UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

blockers; Body Mass Index (BMI); Carvedilol; Diabetes; Hypertension; Metoprolol; Weight

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE; INSULIN; METOPROLOL TARTRATE;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; HYPERTENSION; MALE; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; WEIGHT CHANGE; WEIGHT GAIN;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BODY WEIGHT; CARBAZOLES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; METOPROLOL; MIDDLE AGED; PROPANOLAMINES; PROSPECTIVE STUDIES;

EID: 34250900379     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2006.10.017     Document Type: Article

References (21)

1. Sharma A.M., Pischon T., Hardt S., et al. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. Hypertension 37 (2001) 250-254
2. UKPD Study Group, and UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317 (1998) 713-720
3. Kaplan N.M. Obesity in hypertension: effects on prognosis and treatment. J Hypertens Suppl 16 (1998) S35-S37
4. Giugliano D., Acampora R., Marfella R., et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non- insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 126 (1997) 955-959
5. Jacob S., Rett K., Wicklmayr M., et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 14 (1996) 489-494
6. Bakris G.L., Fonseca V., Katholi R.E., et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292 (2004) 2227-2236
7. Bakris G.L., Bell D.S., Fonseca V., et al. The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial. J Diabetes Complications 19 (2005) 74-79
8. Haffner S.M., Kennedy E., Gonzalez C., et al. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 19 (1996) 1138-1141
9. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 158 (1998) 1855-1867
10. Bogardus C., Lillioja S., Mott D.M., et al. Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol 248 (1985) E286-E291
11. Abbasi F., Brown Jr. B.W., Lamendola C., et al. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 40 (2002) 937-943
12. Kahn B.B., and Flier J.S. Obesity and insulin resistance. J Clin Invest 106 (2000) 473-481
13. Sullivan P.W., Morrato E.H., Ghushchyan V., et al. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. Diabetes Care 28 (2005) 1599-1603
14. Ferrannini E., Haffner S.M., Mitchell B.D., and Stern M.P. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 34 (1991) 416-422
15. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
16. Ueshiba H., and Miyachi Y. Effect of doxazosin on insulin resistance in hypertensive patients with obesity. Horm Metab Res 35 (2003) 532-536
17. Friedman J.M. The function of leptin in nutrition, weight, and physiology. Nutr Rev 60 (2002) S1-S14
18. Ustundag B., Gungor S., Aygun A.D., et al. Oxidative status and serum leptin levels in obese prepubertal children. Cell Biochem Funct (2006) [Epub ahead of print]
19. Suzuki K., Ito Y., Ochiai J., et al. Relationship between obesity and serum markers of oxidative stress and inflammation in Japanese. Asian Pac J Cancer Prev 4 (2003) 259-266
20. Klein S., Burke L.E., Bray G.A., et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 110 (2004) 2952-2967
21. Festa A., and Haffner S.M. Inflammation and cardiovascular disease in patients with diabetes: lessons from the Diabetes Control and Complications Trial. Circulation 111 (2005) 2414-2415